Maia Biotechnology Inc (MAIA) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form D - Notice of Exempt Offering of Securities

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted...

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

Expansion study to enroll patients in the U.S. and select countries in Europe and Asia Multiple milestones attainable for 2025 MAIA...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted...

Form 8-K - Current report

MAIA Biotechnology Announces Private Placement of $2,715,000

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]